P-538 Sequential treatment with docetaxel-cisplatin (DP) doublet allows higher conversion to response for patients (pts) with advanced NSCLC in stable disease (SD) after 2 courses of gemcitabine-cisplatin (GP): Preliminary results of a pilot study